<--- Back to Details
First PageDocument Content
Pharmacology / Clinical research / Drug discovery / Orphan drug / European Medicines Agency / Orphan Drug Act / Pharmaceutical industry / European Organization for Rare Diseases / Rare disease / Pharmaceuticals policy / Pharmaceutical sciences / Health
Date: 2012-02-20 08:19:29
Pharmacology
Clinical research
Drug discovery
Orphan drug
European Medicines Agency
Orphan Drug Act
Pharmaceutical industry
European Organization for Rare Diseases
Rare disease
Pharmaceuticals policy
Pharmaceutical sciences
Health

[removed]Fac sheet OD[removed]:04

Add to Reading List

Source URL: www.eurordis.org

Download Document from Source Website

File Size: 1,30 MB

Share Document on Facebook

Similar Documents

SL-35: Oncology Phenotypic Screening. Macrocycles. Phenotypic screening is a firmly established technology that has contributed to the identification of valuable therapeutic agents in oncology drug discovery [1]. For exa

DocID: 1voSH - View Document

Seminars on Drug Discovery & Development Wednesdays 17::00, Lecture Hall 1, Pharmazentrum, Klingelbergstrasse 50, Basel Feb 24, 16 Prof. Dr. G. Klebe, Institute of Pharmaceutical Chemistry, Philipps-University Mar

DocID: 1vnYL - View Document

THE SCIENCE OF BETTER MEDICINES The Harvard Program in Therapeutic Science (HiTS) is building partnerships and developing new ideas and technologies to advance drug discovery and precision medicine.

DocID: 1vnKo - View Document

Scientific Program conferenceseries.com 3rd International Conference and Expo on Drug Discovery & Designing

DocID: 1vngF - View Document

5th CDDD Meeting COMPUTATIONALLY DRIVEN DRUG DISCOVERY November 16-17, 2017 | IFOM, Milan - Italy

DocID: 1vkVj - View Document